About - Kymera Therapeutics (2022)

Inventing New Possibilities, Transforming Treatment Paradigms

Kymera Therapeutics is a clinical stage biopharmaceutical company pioneering a transformative new modality, “targeted protein degradation” (TPD), with the ability to pursue targets long considered undruggable and to treat disease in entirely new ways. Its mission is to discover, develop and commercialize novel and transformative therapies to improve the lives of patients with serious diseases. Our team has developed a proprietary drug discovery engine, Pegasus, to enable the design of highly selective, small molecule protein degraders with potent activity against a broad range of disease indications. We are committed to selecting targets with the broadest possible impact across multiple disease indications with high unmet medical need to realize the full potential of TPD.

Kymera is led by an expert team of dedicated scientists and drug hunters, with decades of experience in the foundational areas of targeted protein degradation and drug development.

The Kymera Team

Management Team

Board Of Directors

Scientific Advisory Board

Academic Collaborators

Partners

Investors

Management Team

About - Kymera Therapeutics (1)

Management Team

Board Of Directors

Scientific Advisory Board

Academic Collaborators

Partners

Investors

About - Kymera Therapeutics (2)

About - Kymera Therapeutics (3)

Nello Mainolfi, PhD

Co-Founder, President and Chief Executive Officer

Read Bio

About - Kymera Therapeutics (4)

About - Kymera Therapeutics (5)

Nello Mainolfi, PhD

Co-Founder, President and Chief Executive Officer

Nello started his drug discovery career at the Novartis Institutes for Biomedical Research, leading teams to identify multiple novel potential medicines that have entered clinical development across a series of disease areas. Notably he led the team that discovered and developed the first complement factor B inhibitor now in late clinical development across a range of indications. Before founding Kymera, Mainolfi was an Entrepreneur in Residence at Atlas Venture and had previously led discovery research at cancer metabolism startup Raze Therapeutics.Nello has authored >60 papers and patents and has written reviews in the areas of medicinal chemistry, drug discovery and protein degradation. Nello was trained at Imperial College, University of London and The Scripps Research Institute in California.

About - Kymera Therapeutics (6)

About - Kymera Therapeutics (7)

Elaine Caughey, MBA

Chief Business Officer

Read Bio

About - Kymera Therapeutics (8)

About - Kymera Therapeutics (9)

Elaine Caughey, MBA

Chief Business Officer

As Chief Business Officer at Kymera Therapeutics, Elaine brings more than 20 years of experience in the biotechnology industry, including leadership roles in business development, commercial operations, and early-stage investing. Prior to Kymera, Elaine was the Chief Business Officer at Cygnal Therapeutics, a platform company generating preclinical compounds for oncology and inflammation. She spent the majority of her career at Biogen, where she led a number of in-licensing, M&A, and divestitures while in business development. She also served as Head of Strategy and Operations, Global Market Access and Pricing, where she helped build the market access organization and successfully launched several products in multiple sclerosis, hemophilia and rare disease. She began her career in venture capital, investing in early-stage biotech and medical device companies at MPM Capital and Advanced Technology Ventures.Elaine received her BA in Economics from Wellesley College and her MBA from Harvard Business School.

About - Kymera Therapeutics (10)

About - Kymera Therapeutics (11)

Jared Gollob, MD

Chief Medical Officer

Read Bio

About - Kymera Therapeutics (12)

About - Kymera Therapeutics (13)

Jared Gollob, MD

Chief Medical Officer

In his role as CMO, Jared leads clinical development for Kymera Therapeutics, advancing clinical candidates identified by Kymera’s proprietary Pegasus™ targeted protein degradation platform. Jared joined Kymera from Alnylam Pharmaceuticals, where he was Vice President of Clinical Development and Global Vice President of Medical Affairs for Amyloidosis. There, he led early and late stage clinical programs in infectious disease, oncology, and amyloidosis that provided the first proof of concept in humans for RNA interference therapeutics and culminated in the FDA and EMA approvals of ONPATTROTMfor the treatment of hereditary transthyretin amyloidosis. Jared previously held academic positions at Harvard Medical School and Duke University School of Medicine, and was on staff at Dana-Farber Cancer Institute, Beth Israel Deaconess Medical Center and Duke University Medical Center, where he was engaged in both clinical and laboratory research in oncology and immunology. He has authored more than 50 peer-reviewed papers published in top-tier medical and scientific journals. Jared received his BA and MD from Columbia University, and completed clinical training in internal medicine and medical oncology at Massachusetts General Hospital and the Dana-Farber Cancer Institute, respectively.

About - Kymera Therapeutics (14)

About - Kymera Therapeutics (15)

Bruce Jacobs, CFA, MBA

Chief Financial Officer

Read Bio

About - Kymera Therapeutics (16)

About - Kymera Therapeutics (17)

Bruce Jacobs, CFA, MBA

Chief Financial Officer

As CFO, Bruce directs financial operations and investor relations for Kymera Therapeutics. Bruce joined Kymera with more than 25 years of experience in health care financial services, investment banking and equity research. He previously was Managing Partner for Westfield Capital Management, a Boston-based equity investment firm. In addition to his core portfolio management responsibilities, he served on the firm’s Management Committee and as the Health Care Team Lead. Bruce was also a Director with Alex Brown & Sons/Deutsche Bank and part of the health care investment banking group and the equity research team. He graduated magna cum laude from the Wharton School of the University of Pennsylvania, earned a Master of Business Administration from the Harvard Business School and is a Chartered Financial Analyst. Bruce is currently a member of the Board of Directors at Boys & Girls Clubs of Boston and serves on the Board of Advisors for Life Science Cares.

About - Kymera Therapeutics (18)

About - Kymera Therapeutics (19)

Karen Martin, JD, PhD

Vice President, Head of Legal

Read Bio

About - Kymera Therapeutics (20)

About - Kymera Therapeutics (21)

Karen Martin, JD, PhD

Vice President, Head of Legal

As Vice President, Head of Legal at Kymera Therapeutics, Karen is responsible for all aspects of the company’s legal and intellectual property functions. Karen joined Kymera from Takeda Pharmaceuticals (formerly, Shire PLC), where she was Lead IP Counsel, US Business Unit, developing patent and trademark portfolios for assets in the oncology, ophthalmology, and rare disease space, in addition to supporting various post-grant, litigation, diligence, and transactional activities. Karen previously practiced intellectual property law at Wolf Greenfield & Sacks in Boston, MA, where she counseled clients in various technical areas including pharmaceuticals, diagnostics, polymers, sensors, and imaging technologies. Karen obtained her law degree from Suffolk University Law School and holds a PhD in Organic Chemistry from the Massachusetts Institute of Technology and a BS in Chemistry from Boston College.

About - Kymera Therapeutics (22)

About - Kymera Therapeutics (23)

Karen Weisbach

Vice President, People and Culture

Read Bio

About - Kymera Therapeutics (24)

About - Kymera Therapeutics (25)

Karen Weisbach

Vice President, People and Culture

As Vice President, People and Culture, Karen brings more than 15 years of experience in human resources and operations, designing values-based initiatives to enhance company culture, improve employee experience and manage change in dynamic, innovative organizations in the biopharmaceutical industry. Prior to Kymera, she served in human resource leadership roles at bluebird bio, Inc., including building and leading the global People Partner function responsible for driving talent and organizational strategies with an emphasis on employee engagement, development, and performance.

About - Kymera Therapeutics (26)

(Video) Madison Adams, B.S.P.S '18 - Pre-Clinical Study Manager, Kymera Therapeutics

About - Kymera Therapeutics (27)

Brian Albarran, PhD, MBA

Senior Vice President, Corporate Strategy

Read Bio

About - Kymera Therapeutics (28)

About - Kymera Therapeutics (29)

Brian Albarran, PhD, MBA

Senior Vice President, Corporate Strategy

As Senior Vice President, Head of Corporate Strategy at Kymera Therapeutics, Brian is responsible for the development and coordination of strategic initiatives that drive value creation and corporate growth. Brian joined Kymera from TESARO (now a GSK Company) where, as a Program Team Leader, he oversaw the FDA approval of the NK1RA rolapitant/Varubi IV and led multiple clinical programs in immuno-oncology, including the anti-PD-1 dostarlimab/Jemperli. While at TESARO, Brian also built and led the Competitive Intelligence function to support both clinical and commercial oncology programs, including the PARP inhibitor niraparib/Zejula. Brian was previously a strategy consultant at Leerink and Navigant Consulting after numerous biotech roles in process development, manufacturing, and business development at ICOS, Trubion Pharmaceuticals, and Emergent BioSolutions. Brian earned his MBA from the Wharton School of Business and holds a PhD in Bioengineering from the University of Washington and a BSE in Biomedical Engineering from Duke University.

About - Kymera Therapeutics (30)

About - Kymera Therapeutics (31)

Todd Cooper

Senior Vice President, Corporate Affairs

Read Bio

About - Kymera Therapeutics (32)

About - Kymera Therapeutics (33)

Todd Cooper

Senior Vice President, Corporate Affairs

As Senior Vice President, Corporate Affairs,Todd’s career has focused on developing and implementing integrated communications, advocacy and engagement strategies for life science companies. Before joining Kymera,Toddwas Global Head of Science Communications at Sanofi, where he was responsible for strengthening the company’s scientific reputation, highlighting its pipeline and enhancing the culture of the R&D organization. Prior to Sanofi,Toddwas Global Head of Brand and Science Communications atBiogen, where he led internal and external communications supportingBiogen’s marketed products, pipeline programs and R&D organization.AtBiogen, he oversaw six product approvals, and generated awareness of the company’s academic, patient advocacy and industry collaborations and partnerships.Todd graduated from the University of Rochester with a B.A. in English.

Chris De Savi, PhD

Senior Vice President, Head of Drug Discovery

Read Bio

About - Kymera Therapeutics (36)

About - Kymera Therapeutics (37)

Chris De Savi, PhD

Senior Vice President, Head of Drug Discovery

As Senior Vice President, Head of Drug Discovery at Kymera Therapeutics, Chris is responsible for medicinal and computational chemistry, lead discovery (biochemistry, biophysics, structural biology), pre-clinical development (DMPK and Toxicology) and proteomics. His team contributes to all drug discovery phases at Kymera from project inception through to clinical candidate discovery and beyond. Prior to joining Kymera, Chris was head of chemistry at Blueprint Medicines, a precision medicine company specialized in kinase drug discovery and development. Chris has deep experience in leading discovery research groups and project teams in both global pharmaceutical and biotech companies. He has directly contributed to the invention of 9 clinical candidate drugs for oncology and inflammation disease – most recently BLU-945, a EGFR T790M/C797S triple mutant inhibitor for the treatment of lung cancer, AZD4573, a selective CDK9 inhibitor for the treatment of haematological malignancies and AZD9496, an oral, selective estrogen receptor degrader for the treatment of ER+ breast cancer. He co-discovered Barasertib (AZD1152), a selective Inhibitor of Aurora B kinase for the treatment of AML. He is an author of over 50 peer-reviewed publications and patents in the fields of medicinal chemistry and drug discovery and a PhD qualified chemist who has previously held academic positions at Queens’ College Cambridge and University of Cambridge, Cambridge, UK.

About - Kymera Therapeutics (38)

About - Kymera Therapeutics (39)

Kevin Dushney

Senior Vice President, IT and Operations

Read Bio

About - Kymera Therapeutics (40)

About - Kymera Therapeutics (41)

Kevin Dushney

Senior Vice President, IT and Operations

As Vice President of Information Technology at Kymera Therapeutics, Kevin brings over 20 years of experience in information technology (IT) in the biopharmaceutical industry. Kevin has extensive experience in planning, designing, and implementing innovative IT strategies and solutions to support growth across preclinical to commercial-stage organizations. Kevin previously held IT and operations leadership roles at Editas Medicine, Inc., Synageva Biopharma Corp., Zafgen, Inc., and Alnylam Pharmaceuticals. Kevin holds a Bachelor’s degree from the University of Massachusetts Amherst.

About - Kymera Therapeutics (42)

About - Kymera Therapeutics (43)

Ashwin Gollerkeri, MD

Senior Vice President, Head of Development

Read Bio

About - Kymera Therapeutics (44)

About - Kymera Therapeutics (45)

Ashwin Gollerkeri, MD

Senior Vice President, Head of Development

As Senior Vice President, Head of Development at Kymera Therapeutics, Ashwin is responsible for all phases of Kymera’s drug development programs. Ashwin brings more than 20 years of drug development experience, including service at Pfizer Inc., Array BioPharma, Novartis AG, and Bristol-Myers Squibb Company (BMS). As Vice President of Clinical Science-Oncology at Array, Ashwin’s efforts led to successful filings of New Drug Applications for the targeted cancer therapies BRAFTOVI® (encorafenib) and MEKTOVI® (binimetinib). Ashwn has also held various leadership roles in clinical development and research at Pfizer, Novartis, and BMS. Ashwin holds a BA degree in Cell and Developmental Biology from Northwestern University and an MD from the University of Kansas School of Medicine. Ashwin subsequently trained in Internal Medicine and completed a Chief Residency at The Miriam Hospital-Brown University School of Medicine and in Medical Oncology at Yale University School of Medicine.

About - Kymera Therapeutics (46)

About - Kymera Therapeutics (47)

Vijay Sabesan

Senior Vice President, Technical Operations

Read Bio

About - Kymera Therapeutics (48)

About - Kymera Therapeutics (49)

Vijay Sabesan

Senior Vice President, Technical Operations

As Senior Vice President, Technical Operations, Vijay brings over 25 years of experience in the pharmaceutical and biotech industry, including over 10 years in senior leadership roles. Prior to joining Kymera, Vijay was Senior Vice President, Technical Operations at Theravance Biopharma where he was responsible for leading the process R&D, pharmaceutical development, analytical development, supply chain management and CMC project management functions. Vijay has extensive experience in drug development, regulatory interactions, and manufacturing. At Theravance, he led CMC efforts towards commercial approval of VIBATIV® and YUPELRI®, and partnership deals with several large pharma companies. Vijay holds a Bachelor’s Degree from the Indian Institute of Technology Madras, and a Master of Science from Rutgers, The State University of New Jersey, both in Chemical Engineering.

About - Kymera Therapeutics (50)

About - Kymera Therapeutics (51)

Juliet Williams, PhD

Senior Vice President, Head of Biology

Read Bio

About - Kymera Therapeutics (52)

About - Kymera Therapeutics (53)

Juliet Williams, PhD

Senior Vice President, Head of Biology

As Senior Vice President, Head of Biology at Kymera Therapeutics, Juliet brings more than 20 years of drug development experience, including service at Novartis, Sanofi, Millennium, and Curis. Prior to Kymera, Juliet was the Head of Oncology Biology and Small Molecule Drug Discovery at Novartis Institutes for Biomedical Research and served as the Head of Oncology Pharmacology at both Novartis and Sanofi. Juliet holds a degree in Natural Sciences (Biochemistry) from the University of Cambridge and a PhD in Developmental Biology from University College London. Juliet subsequently completed a Wellcome Postdoctoral Fellowship at University College London in Developmental Biology.

About - Kymera Therapeutics (54)

About - Kymera Therapeutics (55)

Jolly Bhatia

Vice President, Quality

Read Bio

About - Kymera Therapeutics (56)

About - Kymera Therapeutics (57)

Jolly Bhatia

Vice President, Quality

(Video) Kymera Therapeutics To Go Public August 21 (KYMR)

As Vice president, Quality, Jolly brings 25 years in quality oversight of manufacturing and clinical trial lifecycle activities including process and product development, clinical and commercial supply chains and new product launch. Prior to Kymera, he served in quality leadership roles at X4 Pharmaceuticals, Inc., Alnylam Pharmaceuticals, Inc., and Genzyme Corporation. He holds a Bachelor of Pharmacy degree from Birla Institute of Technology and Science and a Master’s degree in Industrial Pharmacy from St. John’s University.

About - Kymera Therapeutics (58)

About - Kymera Therapeutics (59)

Melissa Brody

Vice President, Business Development

Read Bio

About - Kymera Therapeutics (60)

About - Kymera Therapeutics (61)

Melissa Brody

Vice President, Business Development

As Vice President, Business Development, Melissa brings nearly a decade of experience in the biotechnology industry advising biopharma companies on strategic transactions. Prior to Kymera, Melissa was a Principal at Aquilo Partners, a boutique life sciences investment bank, where she was responsible for leading the execution of collaborations, licensing transactions, private placements, and mergers and acquisitions across a variety of therapeutic areas, including Kymera in its collaboration with Sanofi, Disarm in its sale to Lilly, and Protomer in its sale to Lilly. Melissa earned herBachelor’s in Biology and Ecology (Phi Beta Kappa) from the University of Georgia, where she also played on the Georgia Bulldogs NCAA Division I Women’s Varsity Golf team.

About - Kymera Therapeutics (62)

About - Kymera Therapeutics (63)

Jeff Davis, MBA

Vice President, Head of Clinical Operations

Read Bio

About - Kymera Therapeutics (64)

About - Kymera Therapeutics (65)

Jeff Davis, MBA

Vice President, Head of Clinical Operations

As Vice President, Head of Clinical Operations at Kymera Therapeutics, Jeff is responsible for operational oversight and execution of all Kymera development programs. Jeff joined Kymera from FORMA Therapeutics where he performed a similar role of building out a development organization that scaled with the growing pipeline. Jeff has supported development programs focused in hematologic malignancies, blood and metabolic disorders. Prior to FORMA, Jeff helped oversee execution of the development programs and life cycle management for Iclusig® and Alunbrig® in CML and NSCLC, respectively. Jeff has also held similar positions at Biogen and Ziopharm Oncology. Jeff earned his MBA in Health Sector Management from Boston University and his BS in Biochemistry from Bates College.

About - Kymera Therapeutics (66)

About - Kymera Therapeutics (67)

Xin Huang, PhD

Vice President, Structural Biology, Protein Sciences, and Platform Discovery

Read Bio

About - Kymera Therapeutics (68)

About - Kymera Therapeutics (69)

Xin Huang, PhD

Vice President, Structural Biology, Protein Sciences, and Platform Discovery

As Vice President, Structural Biology, Protein Sciences, and Platform Discovery, Xin brings over 22 years of deep research and development experience in both small molecule and biologic drug discovery to Kymera Therapeutics. Prior to joining Kymera, Xin was head of structural biology & protein sciences at IFM Therapeutics and Amgen, where he and his group carried out structural-based drug discovery of protein targets, including protein-protein interactions (PPIs) in various therapeutic areas, resulting in clinical candidate drugs including AMG232 (a MDM2-p53 PPI inhibitor) and AMG176 (a Mcl1 PPI inhibitor), and recently approved AMG510 (a KRasG12C inhibitor). He has authored 54 peer-reviewed publications in the fields of structural biology, protein sciences, and drug discovery, which have been featured in top tier journals such as Nature, Natural Structural Biology, Cancer Cell, Journal of American Chemical Society, and held a variety of patents. Xin received a PhD from Columbia University and trained as a research fellow at University of North Carolina-Chapel Hill and Dana Farber Cancer Institute/Harvard Medical School.

About - Kymera Therapeutics (70)

About - Kymera Therapeutics (71)

Aimee Mishkin

Vice President, Regulatory Affairs

Read Bio

About - Kymera Therapeutics (72)

About - Kymera Therapeutics (73)

Aimee Mishkin

Vice President, Regulatory Affairs

As Head of Regulatory Affairs, Aimee is responsible for oversight and management of the Regulatory Affairs function at Kymera, including nonclinical, CMC and clinical regulatory strategies for all Kymera development candidates. Aimee has over 15 years of regulatory affairs experience in the biotechnology industry, serving as the lead regulatory strategist for several commercially successful medicines. Before joining Kymera, Aimee gained significant experience in small and midsized companies, with increasing levels of responsibility and leadership roles through her tenure at Forma Therapeutics, Clovis Oncology, Array BioPharma and OSI Pharmaceuticals. She has supported early and late-stage drug development programs in multiple therapeutic areas and has extensive experience in biotech-pharma co-development partnerships, regulatory intelligence research and due diligence, as well as clinical development plan execution. Aimee is a passionate patient advocate in her personal and professional lives with a focus on oncology patient engagement and advocacy and patient-focused drug development. She holds a B.S. in Molecular, Cell and Developmental Biology and a B.A in English Literature from the University of Colorado, and an M.S. in Pharmacology and Toxicology from Michigan State University.

Aimee also serves as the Program Team Leader of Kymera’s IRAKiMID program, KT-413, currently under development for MYD88-mutant Diffuse large B-cell lymphoma, or DLBCL.

About - Kymera Therapeutics (74)

About - Kymera Therapeutics (75)

Anthony Slavin, PhD

Vice President, Immunology

Read Bio

About - Kymera Therapeutics (76)

About - Kymera Therapeutics (77)

Anthony Slavin, PhD

Vice President, Immunology

As Vice President, Immunology at Kymera Therapeutics, Anthony leads the Immunology team at Kymera Therapeutics and brings deep research and development experience in both small molecule and biologic drug discovery. He has been involved in multiple aspects of drug discovery and development in pharmaceutical and biotechnology companies in the U.S. for more than 20 years, leading discovery, and pharmacology teams, as well as being involved in efforts focused on the external identification and diligence of novel technologies and assets suitable for in-licensing and/or acquisition. Prior to joining Kymera, Anthony held leadership positions in Immunology at Abbvie and Boehringer Ingelheim, where he oversaw research departments dedicated to identifying and developing therapeutics for grievous autoimmune diseases, including the recently approved SKYRIZI, a monoclonal antibody targeting IL-23. He started his career at Tularik which was acquired by Amgen, and was a group leader at the Genomics Institute of the Novartis Research Foundation (GNF). Anthony holds a BSc (Hons.) and a PhD degree from the University of Melbourne and trained as a research fellow at Harvard Medical School and Stanford University.

About - Kymera Therapeutics (78)

About - Kymera Therapeutics (79)

Michael Todisco, MS

Vice President, Accounting & Finance

Read Bio

About - Kymera Therapeutics (80)

About - Kymera Therapeutics (81)

Michael Todisco, MS

Vice President, Accounting & Finance

As Vice President, Accounting & Finance at Kymera, Mike is responsible for all aspects of the company’s finance operations. Mike joined Kymera with over 25 years of experience, including 15 years in biotechnology. Mike was most recently Vice President Finance & Controller at Pear Therapeutics, and prior to that held Vice President positions at Karyopharm, Dicerna, BG Medicine and Dusa Pharmaceuticals. Earlier in his career, Mike spent time in public accounting with EY and KPMG in the audit practice. Mike obtained a BA in Economics from Colgate University and an MS in Accountancy from Northeastern University.

About - Kymera Therapeutics (82)

About - Kymera Therapeutics (83)

Nello Mainolfi, PhD

Co-Founder, President and Chief Executive Officer

Read Bio

About - Kymera Therapeutics (84)

About - Kymera Therapeutics (85)

Nello Mainolfi, PhD

Co-Founder, President and Chief Executive Officer

Nello started his drug discovery career at the Novartis Institutes for Biomedical Research, leading teams to identify multiple novel potential medicines that have entered clinical development across a series of disease areas. Notably he led the team that discovered and developed the first complement factor B inhibitor now in late clinical development across a range of indications. Before founding Kymera, Mainolfi was an Entrepreneur in Residence at Atlas Venture and had previously led discovery research at cancer metabolism startup Raze Therapeutics.Nello has authored >60 papers and patents and has written reviews in the areas of medicinal chemistry, drug discovery and protein degradation. Nello was trained at Imperial College, University of London and The Scripps Research Institute in California.

About - Kymera Therapeutics (86)

About - Kymera Therapeutics (87)

Bruce Booth, DPhil

Chairman and Co-Founder

Read Bio

(Video) Kymera Therapeutics IPO (KYMR) + Updates and Analysis on HRMY, INBX & NNOX: MID-WEEK Edition

About - Kymera Therapeutics (88)

About - Kymera Therapeutics (89)

Bruce Booth, DPhil

Chairman and Co-Founder

Bruce Booth is a partner and focuses on the discovery and development of novel medicines and therapeutic platforms.

Bruce is currently chairman of Arkuda Therapeutics, AvroBio (NASDAQ:AVRO), Hotspot Therapeutics, Kymera Therapeutics (NASDAQ:KYMR), Nimbus Therapeutics, and Quench Bio. He also serves on the board of Magenta Therapeutics (NASDAQ:MGTA) and several seed stage companies. He previously served on the boards of past Atlas companies Avila (acquired by Celgene), Lysosomal Therapeutics, miRagen (NASDAQ:MGEN), Padlock (acquired by BMS), Prestwick (acquired by Biovail), Rodin Therapeutics (acquired by Alkermes), Stromedix (acquired by Biogen), Unum Therapeutics (NASDAQ:UMRX), and a number of other ventures.

Bruce serves or has served as an advisor in various capacities to Takeda, UCB, and the Gates Foundation. He also serves on the boards of the Pennsylvania State Research Foundation, which helps with technology transfer for Penn State, and New England Disabled Sports, a charity dedicated to adaptive sports. Bruce blogs about biotech and venture capital topics at LifeSciVC.com, which is syndicated on Forbes.

Prior to joining Atlas in 2005, Bruce was a consultant at McKinsey & Company, as well as an investor for Caxton Health Holdings. As a British Marshall Scholar, Bruce received a DPhil (PhD) in molecular immunology from Oxford University. He received a BS in biochemistry, summa cum laude, from The Pennsylvania State University.

Bruce enjoys running, skiing, hiking, and fly fishing. He lives in Wellesley, MA and has three wonderful kids.

About - Kymera Therapeutics (90)

About - Kymera Therapeutics (91)

Jeff Albers, JD, MBA

Read Bio

About - Kymera Therapeutics (92)

About - Kymera Therapeutics (93)

Jeff Albers, JD, MBA

Jeff Albers has more than 15 years of experience bringing important new medicines to patients with cancer and rare diseases in leadership roles in the biopharmaceutical industry. In 2014, he joined Blueprint Medicines as Chief Executive Officer and member of the board of directors and led the research-stage company through an initial public offering. Since that time, Blueprint Medicines has evolved into a leading precision medicine company with a global, fully integrated business, including one FDA-approved therapy and a rapidly advancing pipeline. Jeff previously served as President of Algeta, where he oversaw the successful commercial launch of a targeted cancer therapy prior to the company’s acquisition by Bayer. Prior to Algeta, he held senior commercial and corporate development positions at Genzyme (now a division of Sanofi), most recently as vice president of the U.S. hematology and oncology business unit. Earlier in his career, Jeff was a life sciences corporate attorney at Mintz Levin Cohn Ferris Glovsky & Popeo. He currently serves on the board of directors at Magenta Therapeutics and the Eastern New England Chapter of the American Cancer Society and is on the Board of Advisors for Life Sciences Cares. He holds a BS from Indiana University and an MBA and JD from Georgetown University.

About - Kymera Therapeutics (94)

About - Kymera Therapeutics (95)

Pamela Esposito, PhD

Read Bio

About - Kymera Therapeutics (96)

About - Kymera Therapeutics (97)

Pamela Esposito, PhD

Pamela L. Esposito, PhD is currently the Chief Business Officer of Replimune (NASDAQREPL). Since its inception, Pamela has been responsible for both corporate and business development, having raised over $400M. Over the past 18 years, Pamela has held a variety of strategy, commercial and business development positions in small biotech companies, playing lead roles in transformative deals for each company. Previously, she was Chief Business Officer at Ra Pharmaceuticals (NASDAQ RARX). As an early member of Ra’s senior management team, Pamela played a leadership role in strategy, helping Ra transform from a discovery platform to a clinical stage company and raising approximately $58 million in a Series B mezzanine funding round. Prior to Ra, she was VP of Business Development at Biovex and led the negotiation of the acquisition of the company by Amgen. Early in her career, she was a director at Bioduro based in Beijing, China and Vion Pharmaceuticals in New Haven, CT. Currently, Pamela sits on the board of directors of Accent Therapeutics. Pamela earned a PhD in pharmacology from Tufts University School of Medicine and a BA from Dartmouth College.

About - Kymera Therapeutics (98)

About - Kymera Therapeutics (99)

Joanna Horobin, MB, ChB

Read Bio

About - Kymera Therapeutics (100)

About - Kymera Therapeutics (101)

Joanna Horobin, MB, ChB

Joanna Horobin, MB, ChB, is the former Senior Vice President and Chief Medical Officer of Idera Pharmaceuticals, Inc. Prior to joining Idera in November 2015, Dr. Horobin was most recently the Chief Medical Officer of Verastem, Inc. and previously served as Chief Executive Officer of Syndax Pharmaceuticals. Additionally, Dr. Horobin held several roles of increasing responsibility at global pharmaceutical corporations such as Rhône-Poulenc Rorer (now Sanofi) where she spearheaded the launch of the global Oncology business unit which included the commercial introduction of Taxotere®(docetaxel) in breast cancer and Campto/Camptosar®(CPT11) for colorectal cancer. Dr. Horobin also led a successful joint venture with Chugai to launch Granocyte®(lenograstim). Prior, Dr. Horobin played significant leadership roles in the approvals of Lovenox®, Celectol®, Augmentin®, Timentin®, temocillin, Bactroban®and Relafen®/Reliflex®.

Dr. Horobin currently serves as a Non-Executive Director of Nordic Nanovector ASA. Dr. Horobin received her medical degree from the University of Manchester, United Kingdom.

About - Kymera Therapeutics (102)

About - Kymera Therapeutics (103)

Gorjan Hrustanovic, PhD

Read Bio

About - Kymera Therapeutics (104)

About - Kymera Therapeutics (105)

Gorjan Hrustanovic, PhD

Dr. Gorjan Hrustanovic is Managing Director at BVF Partners L.P., where he focuses on biotech and therapeutic investments. Gorjan is currently serving on the board of Rain Therapeutics, Inc., Olema Pharmaceuticals, Inc, and is also a board observer at 4D Molecular Therapeutics.

Prior to joining BVF in 2015, Gorjan received his PhD in Cancer Biology & Cell Signaling at the University of California, San Francisco (UCSF), where he also co-founded a small biotech-focused investment fund. At UCSF, his research focus was personalized medicine and molecularly targeted therapy in non-small cell lung cancer. His research in cancer biology is published in peer-reviewed journals such as Nature Medicine, Oncogene, Cell Reports, and others. Gorjan earned his BS degree in Molecular Biology, and a BS in Economics/Management Science from UCSD.

About - Kymera Therapeutics (106)

About - Kymera Therapeutics (107)

John Maraganore, PhD

Read Bio

About - Kymera Therapeutics (108)

About - Kymera Therapeutics (109)

John Maraganore, PhD

Dr. John Maraganore served as the founding CEO and a Director of Alnylam from 2002 to 2021, where he built and led the company from early platform research on RNA interference through global approval and commercialization of the first four RNAi therapeutic medicines, ONPATTRO®, GIVLAARI®, OXLUMO®, and Leqvio®. At Alnylam, he also led the company’s value creation strategy, building $25B in market capitalization, including over 20 major pharmaceutical alliances. He continues to serve on the Alnylam Scientific Advisory Board. Prior to Alnylam, he served as an officer and a member of the management team for Millennium Pharmaceuticals, Inc., where he was responsible for the company’s product franchises in oncology, and cardiovascular, inflammatory and metabolic diseases, in addition to leadership of M&A, strategy, and biotherapeutics functions. Before Millennium, he served as Director of Molecular Biology and Director of Market and Business Development at Biogen, Inc. where he invented and led the discovery and development of ANGIOMAX® (bivalirudin) for injection. Previously, he was a scientist at ZymoGenetics, Inc. and the Upjohn Company. Dr. Maraganore received his M.S. and Ph.D. in biochemistry and molecular biology at the University of Chicago. He is currently a Venture Partner at ARCH Venture Partners, a Venture Advisor at Atlas Ventures, and an Executive Partner at RTW Investments. He is also Chair of the Board of Directors of Hemab Therapeutics and a member of the Board of Directors of Agios Pharmaceuticals, Beam Therapeutics and the Biotechnology Industry Organization, where he was Chair from 2017-2019. In addition, he serves on the Board of the Termeer Foundation – committed to continuing the legacy of the late Henri A. Termeer, as Chair of the n-Lorem Foundation Advisory Council – committed to meeting the needs of patients with nano-rare diseases, and as a strategic advisor to SalioGen, SQZ Biotechnologies, and other innovative companies.

About - Kymera Therapeutics (110)

About - Kymera Therapeutics (111)

Leigh Morgan

Read Bio

About - Kymera Therapeutics (112)

About - Kymera Therapeutics (113)

Leigh Morgan

Leigh Morgan is a senior executive with experience scaling profitable, high-performing organizations in the global biopharmaceutical, philanthropy, and public sectors. Ms. Morgan is currently Chief Strategy and Operating Officer for Nia Tero, a US-based non-profit working in solidarity with Indigenous peoples and movements worldwide. She is a key architect of the firm’s growth, inclusive of strategy, finance, innovation, communications, operations, impact investments and governance. Ms. Morgan also serves Vice-Chair/Chair-elect on the board of the Fred Hutch Cancer Center, is on the University of Washington Medical Center Advisory Board, and is an independent director at Curemark, a clinical-stage biotechnology company. Previously, she served as Chief Operating Officer of the Bill & Melinda Gates Foundation, where she oversaw a broad portfolio, including human resources, information technology and security, facilities and the foundation’s culture transformation efforts. Prior to these positions, she held roles as Associate Chancellor at the University of California, San Francisco, Vice President and Global Head of Human Resources for Product Development at Genentech, and HR leadership roles at GSK. She holds a master’s degree in organization development from the American University and a bachelor’s degree from Duke University. She was awarded an honorary doctorate from the Asian University for Women in Bangladesh and is a member of the Council on Foreign Relations.

About - Kymera Therapeutics (114)

About - Kymera Therapeutics (115)

Donald W. Nicholson, PhD

Read Bio

About - Kymera Therapeutics (116)

About - Kymera Therapeutics (117)

Donald W. Nicholson, PhD

Dr. Don Nicholson is the former Chief Executive Officer of Nimbus Therapeutics. He joined from Merck, where he held various strategic, leadership and operational roles in diverse therapeutic areas, including respiratory, inflammation, immunology, bone, endocrine, urology, infectious disease and neurosciences. He began his career in 1998 at the Merck-Frosst Centre for Therapeutic Research in Montreal and advanced through various positions of increasing responsibility including Vice President & Site Head of the Merck Neurosciences Research site in San Diego, and most recently as Vice President and Worldwide Discovery Head for the Respiratory & Immunology Franchise, based in Kenilworth, N.J. Don has co-authored more than 150 publications in peer-reviewed scientific and medical journals and is internationally recognized for his contributions to the field of apoptotic cell death. He received his PhD. and an Honors BSc. degree in Biochemistry from the University of Western Ontario, and trained as a Medical Research Council postdoctoral fellow at the University of Munich in Germany. He is the recipient of multiple academic and professional honors.

About - Kymera Therapeutics (118)

About - Kymera Therapeutics (119)

Elena Ridloff, CFA

Read Bio

About - Kymera Therapeutics (120)

About - Kymera Therapeutics (121)

Elena Ridloff, CFA

Elena Ridloff has over 20 years of experience in finance and the life sciences industry. She is currently the Chief Financial Officer of a stealth biotechnology company. Previously she was Executive Vice President and Chief Financial Officer for ACADIA Pharmaceuticals where she was responsible for leading corporate finance, accounting, investor relations and corporate affairs functions. Prior to joining Acadia, Ms. Ridloff was Vice President, Investor Relations at Alexion Pharmaceuticals and served as a member of the Operating Committee. Additionally, Ms. Ridloff was Chief Executive Officer and Managing Member of BIOVISIO, an independent consulting firm serving the life sciences industry. She was also a Managing Director at Maverick Capital, a hedge fund based in New York, and was responsible for investments in the biotechnology, pharmaceutical, medical device, and life science sectors. She currently serves on the Board of Directors of Kronos Bio, Inc.

Ms. Ridloff received her BA in History and Sociology of Science from the University of Pennsylvania. She is also a CFA© charterholder.

(Video) 🔴 Kymera Therapeutics Inc. KYMR Stock Trading Facts 🔴

Senior Director of Proteomics, Broad Institute

Professor, Rockefeller University and Investigator, Howard Hughes Medical Institute

Associate Professor, Oncology, Dana-Farber Cancer Institute

Chief Scientific Officer, Bicycle Therapeutics

American Cancer Society Professor and Director of the Center for Lymphoid Malignancies, Columbia University

Chair, Department of Biochemistry and Molecular Pharmacology, New York University School of Medicine and Investigator, Howard Hughes Medical Institute

Professor of General Pathology, Humanitas Clinical and Research Center

Professor of Chemistry, Yale University

Professor, Rheumatology, University of California San Diego

Professor of Pharmacology, University of Washington and Investigator, Howard Hughes Medical Institute

Working at Kymera

Alice McDonald | Length: 20 seconds

(Video) Nello Mainolfi on the Principle Steps of Targeted Protein Degradation

Matt Weiss | Length: 23 seconds

FAQs

Who founded kymera? ›

Nello Mainolfi - Founder, President and Chief Executive Officer - Kymera Therapeutics | LinkedIn.

What does relay therapeutics do? ›

Company Overview

We are a clinical-stage precision medicines company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients.

What is KT 474? ›

KT-474 is a potent, highly selective, orally bioavailable IRAK4 degrader, for the treatment of IL-1R/TLR-driven conditions and diseases with high unmet medical need, including HS and AD, our first indications of focus, as well as RA and other diseases.

What is targeted protein degradation? ›

Targeted protein degradation is an emerging therapeutic modality whereby small-molecule ligands are used to redirect the cellular protein homeostasis machinery. As part of cellular processes, proteins are specifically recruited to E3 ubiquitin ligases and tagged for destruction with chains of ubiquitin1,2.

How many employees does kymera therapeutics have? ›

Kymera Therapeutics corporate office is located in 200 Arsenal Yards Blvd Ste 230, Watertown, Massachusetts, 02472, United States and has 144 employees.

When was kymera therapeutics founded? ›

Who founded relay Therapeutics? ›

Alexis Borisy is chairman of Relay Therapeutics' board of directors, having been the founding investor and CEO of the company.

What are therapeutics examples? ›

Examples of therapeutics include drug therapy, medical devices, nutrition therapy and stem-cell therapies. Therapeutics can be used in patients with active disease – to treat the disease itself or its signs and symptoms – in preventive medicine, or as palliative care.

What is protac technology? ›

Proteolysis targeting chimeric (PROTAC) technology is an effective endogenous protein degradation tool developed in recent years that can ubiquitinate the target proteins through the ubiquitin-proteasome system (UPS) to achieve an effect on tumor growth.

Who invented PROTACs? ›

Kathleen M. Sakamoto reported the first bifunctional or hybrid molecule named PROTAC, which recruits the ubiquitin‐proteasome system, where an E3 ubiquitin ligase is linked to target proteins for degradation.

Where does protein degradation occur? ›

In all tissues, the majority of intracellular proteins are degraded by the ubiquitin (Ub)–proteasome pathway (UPP) (2). However, extracellular proteins and some cell surface proteins are taken up by endocytosis and degraded within lysosomes.

Videos

1. Behind the Bell: Kymera
(Nasdaq)
2. Overlooked Stocks: ISEE, KYMR, RXN
(TD Ameritrade Network)
3. KYMR Price and Volume Analysis by 650 Day Look Back KYMR Stock Analysis for Kymera Therapeutics Stoc
(TickerDD)
4. Cramer: This biotech stock could be worth over $100 billion on an FDA approval
(CNBC Television)
5. Laurent Audoly on Targeted Protein Degradation's Therapeutic Value
(Kymera Therapeutics)
6. Captor Therapeutics one year after IPO
(Strefa Inwestorów)

Top Articles

Latest Posts

Article information

Author: Nathanial Hackett

Last Updated: 01/25/2023

Views: 6180

Rating: 4.1 / 5 (52 voted)

Reviews: 83% of readers found this page helpful

Author information

Name: Nathanial Hackett

Birthday: 1997-10-09

Address: Apt. 935 264 Abshire Canyon, South Nerissachester, NM 01800

Phone: +9752624861224

Job: Forward Technology Assistant

Hobby: Listening to music, Shopping, Vacation, Baton twirling, Flower arranging, Blacksmithing, Do it yourself

Introduction: My name is Nathanial Hackett, I am a lovely, curious, smiling, lively, thoughtful, courageous, lively person who loves writing and wants to share my knowledge and understanding with you.